Isoquercetin Ameliorates Osteoarthritis via Nrf2/ NF ‐ κB Axis: An In Vitro and In Vivo Study
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14620 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2024. Written by He Yu and 6 co-authors. Institution: Department of Orthopaedics, Zhejiang Hospital, Zhejiang, Hangzhou, China. Major MEDLINE topics: Chondrocytes, NF-E2-Related Factor 2, NF-kappa B, Osteoarthritis. Cited 2 times so far (Crossref); 53 references. Funded by: Zhejiang Province Traditional Chinese Medicine Science and Technology Project.
Abstract (original language)
Osteoarthritis (OA) is a progressive joint disease characterized by extracellular matrix (ECM) degradation and inflammation, which is involved with pathological microenvironmental alterations induced by damaged chondrocytes. However, current therapies are not effective in alleviating the progression of OA. Isoquercetin is a natural flavonoid glycoside compound that has various pharmacological effects including anticancer, anti‐diabetes and blood lipid regulation. Previous evidence suggests that isoquercetin has anti‐inflammatory properties in various diseases, but its effect on OA has not been investigated yet. In this study, through western bolt, qRT‐PCR and ELISA, it was found that isoquercetin could reduce the increase of ADAMTS5, MMP13, COX‐2, iNOS and IL‐6 induced by IL‐1β, suggesting that isoquercetin could inhibit the inflammation and ECM degradation of chondrocytes. Through nuclear‐plasma separation technique, western blot and immunocytochemistry, it can be found that Nrf2 and NF‐κB pathways are activated in this process, and isoquercetin may rely on this process to play its protective role. In vivo, the results of X‐ray and SO staining show that intra‐articular injection of isoquercetin reduces the degradation of cartilage in the mouse OA model. In conclusion, the present work suggests that isoquercetin may benefit chondrocytes by regulating the Nrf2/NF‐κB signaling axis, which supports isoquercetin as a potential drug for the treatment of OA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Orthopaedics, Zhejiang Hospital, Zhejiang, Hangzhou, China.
- Department of Orthopedic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
- Center for Drug Delivery System Research, School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.
ORCID profiles: Jungao Zhu
Funding
- Zhejiang Province Traditional Chinese Medicine Science and Technology Project
Cite
APA
Yu, H., Lou, J., Ni, L., Yan, M., Zhu, K., Mao, S., & Zhu, J. (2024). Isoquercetin Ameliorates Osteoarthritis via Nrf2/ NF ‐ κB Axis: An In Vitro and In Vivo Study. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14620
Vancouver
Yu H, Lou J, Ni L, Yan M, Zhu K, Mao S, et al. Isoquercetin Ameliorates Osteoarthritis via Nrf2/ NF ‐ κB Axis: An In Vitro and In Vivo Study. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14620
BibTeX
@article{Yu2024,
author = {Yu, He and Lou, Junsheng and Ni, Libin and Yan, Minwei and Zhu, Kewu and Mao, Su and Zhu, Jungao},
title = {Isoquercetin Ameliorates Osteoarthritis via Nrf2/ NF ‐ κB Axis: An In Vitro and In Vivo Study},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14620}
}
EUVIMED